RCS - EMV Capital PLC - Wanda Health: Fundraising and Business Update

EMV CapitalAnnouncement

10/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251210:nRSJ9121Ka&default-theme=true

RNS Number : 9121K  EMV Capital PLC  10 December 2025

For release on Reach: 07.00, 10 December 2025

 

EMV Capital plc

(EMVC or Group)

Wanda Health: Fundraising and Business Update

EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment
group, is delighted to announce that its portfolio company Wanda Connected
Health Systems Limited (Wanda), the intelligent platform for Remote Patient
Monitoring and Virtual Care, has successfully closed a fundraising of £0.86
million (Fundraising) following a period of strong commercial progress and
growing demand for its platform. A business update on Wanda also follows.

Fundraising

The Fundraising was led and syndicated by EMV Capital Partners Limited
(EMVCP), the Group's wholly owned venture capital and corporate finance firm.
Wanda also is supported through EMV Capital's Venture Build programme.

The Fundraising includes £0.60 million of equity investment and £0.26
million through a loan facility. In addition, warrants have been exercised
over shares worth £0.60 million. The proceeds from the Fundraising will be
used to accelerate Wanda's scale-up of operations with key customers in the
US, further product development, and further execution of its commercial
strategy. The additional capital will ensure Wanda can maintain its rapid
execution pace while meeting rising demand for better chronic disease
management and sustainable alternatives to rising drug costs in the US
healthcare market.

Following the completion of the Fundraising, the Group's total equity holding
in Wanda is 16.5 per cent, which equates to a post-investment fair value of
£1.7 million. This represents a c.15 per cent. increase compared to the fair
value amount of £1.5 million at 30 June 2025.

In addition, following the introduction of investors to Wanda by EMVCP, the
Group's third party assets under management with Wanda is 29.6 per cent. of
Wanda's share capital, which equates to a post-investment fair value of c.
£3.1 million. This represents a c.43 per cent. increase compared to the fair
value amount of £2.1 million at 30 June 2025.

The above percentage holdings are based on fully diluted share capital
excluding convertible loan arrangements.

Business update

Commercial momentum

During 2025 Wanda experienced a period of significant commercial progress,
driven by rising interest from US health plans, employers and PBMs, who are
seeking sustainable approaches to managing cardiometabolic disease and GLP-1
medication use. Over the past year, the company has launched its GLP-1
weight-management programme, released its enhanced cardiometabolic mobile app,
and deployed its new Insights Engine, which is an analytics and AI layer that
transforms all platform, device and coaching data into clear, actionable
insights.

The company has out-competed several billion-dollar competitors to win
multi-million-dollar contracts, has achieved consistent double-digit month on
month growth, and expects to exceed $5 million ARR by the end of 2026.

Wanda's CEO, Tom Smith, presented a detailed update on the company's
commercial traction and 2026 outlook at EMV Capital's Meet the Portfolio
event. The full presentation and investor Q&A can be accessed at:
https://emvcapital.com/news/media/ (https://emvcapital.com/news/media/)

Market Outlook

Wanda operates in one of the largest and fastest-growing healthcare markets
globally. Chronic conditions account for 90% of total US healthcare spend, and
GLP-1 drugs have become the fastest-growing category in the market, now
averaging more than $10,000 per member per year. These sectors represent
multi-billion-dollar opportunities in the US alone, and the global Remote
Patient Monitoring market is forecast to reach around $110.7 billion by 2033,
growing at a CAGR of 19.8% from 2025 to 2033¹. With increasing demand and a
platform designed for scale, Wanda is well positioned to capture long-term
value in this rapidly expanding sector.

[(1) Grand View Research, "Remote Patient Monitoring System Market Report,"
2024.]

Appointment of New Chair

To support its next stage of growth, Wanda recently appointed Michael Steel as
Chair. Michael brings a unique combination of operational leadership, board
experience, and healthcare scale-up expertise. He founded Greenbrook
Healthcare, a respected provider of urgent care services to the NHS and grew
it into a £40m+ revenue organisation employing more than 700 staff.

As Chair, Michael will work closely with the leadership team to advance
commercial execution, accelerate strategic partnerships, and support the
rollout of Wanda's platform.

 

Dr Ilian Iliev, CEO of EMV Capital and Wanda Investment Director, commented:

"We are very pleased to see Wanda complete this fundraise at a time when
demand for sustainable virtual-care solutions is rising sharply across the US
healthcare market. Over the past year, Wanda has demonstrated strong
commercial traction, a clear value proposition for payers, and the ability to
compete successfully against major market leaders. We look forward to
supporting Wanda through EMV Capital's Venture Build programme as it continues
building scale and delivering meaningful value to healthcare systems and
patients in the US and beyond."

 

-Ends-

 

 For more information, please contact:
 EMV Capital plc                                                             via Rosewood
 Ilian Iliev, CEO

 Panmure Liberum (UK) Limited (NOMAD and Broker)                             +44 (0)20 7886 2500
 Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 Rosewood (Financial PR)                                                     +44 (0)20 7653 8702
 John West / Llewellyn Angus / Lily Pearce

 

About EMV Capital plc (EMVC)

EMV Capital plc, is a deep tech and life sciences venture capital investment
group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the
fast-growing sectors and technologies that will define our future; EMV Capital
invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its
portfolio companies, creating an evergreen structure that supports extensive
growth and value creation. EMV Capital's investment thesis is realised through
these capital sources:

·     capital-efficient investments through Group balance sheet;

·     fund management of the Evergreen EIS and Martlet Capital Funds;

·     syndicated investments leveraging its network of third-party
investors.

EMV Capital's approach is characterised by its proactive management style,
aiming to advance portfolio companies to critical value inflection points by
actively engaging with them. Companies are supported through Board
representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international
links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

For more information, visit www.emvcapital.com (http://www.emvcapital.com)

About Wanda

Wanda Health is an intelligent platform for remote patient monitoring and
virtual care. Wanda Health is empowering healthcare providers and payers with
early detection of exacerbations in patients with acute, chronic, and
specialty diseases, helping them speed interventions, prevent adverse events,
and improve patient adherence.

The company is building on many years of research, including UCLA developed
technologies focused on intelligent remote monitoring of physiological data,
patient engagement and healthcare analytics for post-acute care, chronic
disease patients and population health. Wanda's platform enables the control
and reduction of hospitalisation and readmission rates through a Remote
Patient Monitoring System that collects data from patients' homes or community
settings and provides it to clinicians, highlighting high-risk cohorts.

Wanda also uses its comprehensive multi-modality patient engagement tools to
ensure that adherence to treatment protocols increases, improving patient
outcomes. This patient centric approach to care model delivery, combined with
secure computing and revolutionary data mining and analytics provides
actionable insights to the care provider to improve patient outcomes, whilst
reducing cost of care of chronic conditions.

For more information, visit www.wandahealth.com (http://www.wandahealth.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATLBLTMTTMBTA



            Copyright 2019 Regulatory News Service, all rights reserved